STOCK TITAN
  1. Home
  2. News
  3. BRTX

BioRestorative Therapies, Inc. - BRTX STOCK NEWS

Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.

BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.

In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.

The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.

BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.

Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.

For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.

News

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary blinded data from the ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease. The data will be presented at the Orthopaedic Research Society 2024 Annual Meeting. BRTX-100 is a novel cell-based therapeutic evaluated for safety and efficacy in treating cLDD. The company will host a webcasted conference call to review the data on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.52%
Tags
conferences clinical trial
-
News

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Rhea-AI Summary
BioRestorative Therapies, Inc. (BRTX) has been granted a notice of allowance for a U.S. patent related to the Company’s metabolic ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes. This will be the fourth U.S. patent granted under this particular patent family, covering methods of using differentiated human brown fat adipocytes to screen and identify compounds that can activate and regulate metabolic activity. The Company sees this as an important milestone, providing them with tools to screen large libraries of compounds targeting metabolic disorders such as obesity, potentially leading to the development of drugs targeting weight loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
-
News

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Rhea-AI Summary
BioRestorative Therapies CEO to present at ROTH MKM Healthcare Opportunities Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
News

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

Rhea-AI Summary
BioRestorative Therapies strategically positions itself for future growth with expanding manufacturing capacity, increased demand for BRTX-100, and advancements in intellectual property. Roth MKM projects a stock price target of $15 over the next 12 months, compared to the current $2.59. The company had pro forma cash of $13.4 million and $3.3 million remaining in its at-the-market facility. BioRestorative received a unanimous recommendation to continue its Phase 2 trial for evaluating BRTX-100 in patients with chronic lumbar disc disease. The company has made efforts to ramp up manufacturing and quality control capacity and has obtained a license to serve as a tissue bank for processing mesenchymal stem cells. The global mesenchymal stem cell market is expected to grow at a CAGR of 12.8% from 2023 to 2030. BioRestorative can expand its clinical operations and has collaborated with Northwell Health for trial sites. Other companies in the space include Mesoblast, Brainstorm Cell Therapeutic, and Longeveron.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
News

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

Rhea-AI Summary
BioRestorative enters supply agreement with Evolutionary Biologics for cosmetic applications, representing initial venture into $62.8B global aesthetics market. Initial order of 5,000 vials will have positive financial impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.37%
Tags
none
-
News

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

Rhea-AI Summary
BioRestorative announces site activation for BRTX-100 trial in New York, allowing patient recruitment and enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
clinical trial
News

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Rhea-AI Summary
BioRestorative Therapies aims to provide better treatment options for chronic pain without the need for opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
-
News

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) insiders, including Dale Broadrick and CEO Lance Alstodt, demonstrate confidence in the company's future by acquiring shares. Insider buying signals positive outlook and sentiment, providing valuable insights for evaluating potential company performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
News

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
News

BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State

Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) has been granted a license by the New York State Department of Health to operate as a tissue bank, allowing the processing of mesenchymal stem cells for clinical use. This makes BioRestorative the first facility in New York State licensed to do so, setting it apart from competitors. Mesenchymal Stem Cells have the potential to be used in the development of treatments for various diseases, and BioRestorative is excited about the possibilities this presents for their business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
none

FAQ

What is the current stock price of BioRestorative Therapies (BRTX)?

The current stock price of BioRestorative Therapies (BRTX) is $1.55 as of December 20, 2024.

What is the market cap of BioRestorative Therapies (BRTX)?

The market cap of BioRestorative Therapies (BRTX) is approximately 9.9M.

What does BioRestorative Therapies, Inc. specialize in?

BioRestorative Therapies, Inc. specializes in developing regenerative medicine products and therapies using adult stem cells.

What are the main programs developed by BioRestorative Therapies?

The main programs are the Disc/Spine Program and the Metabolic Program, focusing on non-surgical treatment of lumbar disc disease and cell-based therapies for obesity and metabolic disorders, respectively.

What is BRTX-100?

BRTX-100 is a cell therapy product formulated from autologous cultured mesenchymal stem cells intended for the non-surgical treatment of chronic lumbar disc disease.

How does BRTX-100 work?

BRTX-100 involves injecting cultured stem cells into a patient’s damaged disc to alleviate pain caused by protruding and bulging lumbar discs.

What recent partnership has BioRestorative Therapies entered into?

BioRestorative Therapies has signed a five-year exclusive supply agreement with Cartessa Aesthetics to bring cell-based innovations to the aesthetics market.

How financially stable is BioRestorative Therapies?

BioRestorative ended 2023 with approximately $11.1 million in cash and cash equivalents, supplemented by $7.6 million from a private placement.

What are the potential benefits of the partnership with Cartessa Aesthetics?

The partnership aims to commercialize proprietary cell-based products in the aesthetics market, potentially generating significant revenue for BioRestorative.

What is the focus of BioRestorative's Metabolic Program?

The Metabolic Program focuses on developing cell-based therapies for obesity and metabolic disorders using brown adipose-derived stem cells.

Who can I contact for investor relations at BioRestorative Therapies?

You can contact Investor Relations at BioRestorative Therapies by emailing ir@biorestorative.com.

Where can I find more information about BioRestorative Therapies?

More information can be found on their website at www.biorestorative.com.

Stock BRTX logo
BioRestorative Therapies, Inc.

Nasdaq:BRTX

BRTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BRTX Stock Data

9.94M
5.08M
26.61%
13.74%
1.08%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States of America
MELVILLE